// App-Quantinova.ai

4562 : Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (LEN) + everolimus (EVE) versus sunitinib (SUN) treatment arms.

Researchers

Presenter

  • Thomas E. Hutson

Principal Investigators

  • Robert J. Motzer

  • Sun Young Rha

  • Anna Alyasova

  • Jaime R. Merchan

  • Howard Gurney

  • Avivit Peer

  • Toshio Takagi

  • Camillo Porta

  • Thomas Powles

  • Viktor Grnwald

  • Ugo De Giorgi

  • Ulka N. Vaishampayan

  • Manuela Schmidinger

  • Hilary Glen

  • Karla Rodriguez-Lopez

  • Dongyuan Xing

  • Lea Dutta

  • Masatoshi Eto

Medical Centers

  • Texas Oncology, Dallas, TX

  • Dana-Farber Cancer Institute, Boston, MA

  • Memorial Sloan Kettering Cancer Center, New York, NY, Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea

  • Prevoljskiy Region Medical Centre, Novgorod, Russian Federation

  • University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, Macquarie University Hospital, Sydney, NSW, Australia

  • Rambam Health Care Campus, Haifa, Israel

  • Tokyo Women's Medical University, Tokyo, Japan

  • IRCCS San Matteo University Hospital Foundation, Padua, Italy

  • The Royal Free NHS Trust, London, United Kingdom

  • University Hospital of Essen, Essen, Germany

  • Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

  • University of Michigan, Ann Arbor, MI, Medical University of Vienna, Vienna, Austria

  • Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • Merck & Co., Inc., Kenilworth, NJ, Eisai Inc., Woodcliff Lake, NJ, Kyushu University, Fukuoka, Japan

Locations

  • Russia

  • Australia

  • Israel

  • Japan

  • Italy

  • United Kingdom

  • Germany

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Everolimus

  • Lenvatinib

  • Sunitinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT02811861

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved